vs
Pacira BioSciences, Inc.（PCRX）与GIBRALTAR INDUSTRIES, INC.（ROCK）财务数据对比。点击上方公司名可切换其他公司
GIBRALTAR INDUSTRIES, INC.的季度营收约是Pacira BioSciences, Inc.的1.3倍（$225.0M vs $177.4M），GIBRALTAR INDUSTRIES, INC.同比增速更快（24.9% vs 5.0%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -12.3%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
直布罗陀工业公司是专业建筑、基础设施及可再生能源产品制造商与分销商，主营通风系统、屋面配件、太阳能安装支架、园林景观产品等，主要服务北美地区住宅、商业建筑及清洁能源市场，专注提供创新可持续的客户解决方案。
PCRX vs ROCK — 直观对比
营收规模更大
ROCK
是对方的1.3倍
$177.4M
营收增速更快
ROCK
高出19.9%
5.0%
两年增速更快
PCRX
近两年复合增速
-12.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $225.0M |
| 净利润 | $2.9M | — |
| 毛利率 | — | 25.3% |
| 营业利润率 | 3.9% | 7.9% |
| 净利率 | 1.6% | — |
| 营收同比 | 5.0% | 24.9% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.07 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXROCK
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $225.0M | ||
| Q3 25 | $179.5M | $310.9M | ||
| Q2 25 | $181.1M | $309.5M | ||
| Q1 25 | $168.9M | $290.0M | ||
| Q4 24 | $187.3M | $180.1M | ||
| Q3 24 | $168.6M | $277.1M | ||
| Q2 24 | $178.0M | $273.6M |
净利润PCRXROCK
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $-89.1M | ||
| Q2 25 | $-4.8M | $26.0M | ||
| Q1 25 | $4.8M | $21.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $34.0M | ||
| Q2 24 | $18.9M | $32.2M |
毛利率PCRXROCK
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 25.3% | ||
| Q3 25 | 80.9% | 26.6% | ||
| Q2 25 | 77.4% | 28.4% | ||
| Q1 25 | 79.7% | 26.8% | ||
| Q4 24 | 78.7% | 29.0% | ||
| Q3 24 | 76.9% | 29.4% | ||
| Q2 24 | 75.1% | 30.5% |
营业利润率PCRXROCK
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 7.9% | ||
| Q3 25 | 3.5% | 12.8% | ||
| Q2 25 | 4.7% | 12.8% | ||
| Q1 25 | 1.2% | 8.8% | ||
| Q4 24 | 13.2% | 13.3% | ||
| Q3 24 | -82.8% | 15.6% | ||
| Q2 24 | 15.9% | 14.9% |
净利率PCRXROCK
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | -28.6% | ||
| Q2 25 | -2.7% | 8.4% | ||
| Q1 25 | 2.8% | 7.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | 12.3% | ||
| Q2 24 | 10.6% | 11.8% |
每股收益（稀释后）PCRXROCK
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | — | ||
| Q3 25 | $0.12 | $-2.98 | ||
| Q2 25 | $-0.11 | $0.87 | ||
| Q1 25 | $0.10 | — | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $-3.11 | $1.11 | ||
| Q2 24 | $0.39 | $1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $115.7M |
| 总债务越低越好 | — | $0 |
| 股东权益账面价值 | $653.9M | $950.4M |
| 总资产 | $1.2B | $1.4B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资PCRXROCK
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $115.7M | ||
| Q3 25 | $246.3M | $89.4M | ||
| Q2 25 | $445.9M | $43.3M | ||
| Q1 25 | $493.6M | $25.1M | ||
| Q4 24 | $484.6M | $269.5M | ||
| Q3 24 | $453.8M | $228.9M | ||
| Q2 24 | $404.2M | $179.1M |
总债务PCRXROCK
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $0 | ||
| Q3 25 | $376.7M | $0 | ||
| Q2 25 | $580.5M | $0 | ||
| Q1 25 | $583.4M | $0 | ||
| Q4 24 | $585.3M | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 |
股东权益PCRXROCK
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $950.4M | ||
| Q3 25 | $727.2M | $951.8M | ||
| Q2 25 | $757.8M | $1.0B | ||
| Q1 25 | $798.5M | $1.0B | ||
| Q4 24 | $778.3M | $1.0B | ||
| Q3 24 | $749.6M | $1.0B | ||
| Q2 24 | $879.3M | $975.7M |
总资产PCRXROCK
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.5B | $1.5B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.5B | $1.4B | ||
| Q2 24 | $1.6B | $1.4B |
负债/权益比PCRXROCK
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.00× | ||
| Q3 25 | 0.52× | 0.00× | ||
| Q2 25 | 0.77× | 0.00× | ||
| Q1 25 | 0.73× | 0.00× | ||
| Q4 24 | 0.75× | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $35.5M |
| 自由现金流经营现金流 - 资本支出 | — | $26.2M |
| 自由现金流率自由现金流/营收 | — | 11.7% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $120.6M |
8季度趋势，按日历期对齐
经营现金流PCRXROCK
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $35.5M | ||
| Q3 25 | $60.8M | $73.0M | ||
| Q2 25 | $12.0M | $44.9M | ||
| Q1 25 | $35.5M | $13.7M | ||
| Q4 24 | $33.1M | $19.9M | ||
| Q3 24 | $53.9M | $64.7M | ||
| Q2 24 | $53.2M | $36.5M |
自由现金流PCRXROCK
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $26.2M | ||
| Q3 25 | $57.0M | $64.8M | ||
| Q2 25 | $9.3M | $27.3M | ||
| Q1 25 | $26.9M | $2.3M | ||
| Q4 24 | $31.0M | $14.1M | ||
| Q3 24 | $49.8M | $60.5M | ||
| Q2 24 | $51.6M | $33.5M |
自由现金流率PCRXROCK
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 11.7% | ||
| Q3 25 | 31.7% | 20.8% | ||
| Q2 25 | 5.1% | 8.8% | ||
| Q1 25 | 15.9% | 0.8% | ||
| Q4 24 | 16.6% | 7.8% | ||
| Q3 24 | 29.6% | 21.8% | ||
| Q2 24 | 29.0% | 12.2% |
资本支出强度PCRXROCK
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 4.1% | ||
| Q3 25 | 2.2% | 2.6% | ||
| Q2 25 | 1.5% | 5.7% | ||
| Q1 25 | 5.1% | 3.9% | ||
| Q4 24 | 1.1% | 3.3% | ||
| Q3 24 | 2.4% | 1.5% | ||
| Q2 24 | 0.9% | 1.1% |
现金转化率PCRXROCK
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | 1.73× | ||
| Q1 25 | 7.37× | 0.65× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | 2.82× | 1.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
